ONCOVIN
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Jul 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ONCOVIN is a small-molecule injectable chemotherapy agent approved in 1963 for treating hematologic malignancies including peripheral T-cell lymphoma, diffuse large B-cell lymphoma, and non-Hodgkin's lymphoma. The drug's mechanism of action involves microtubule disruption, though specific pharmacologic details are not publicly detailed in available data. It remains a foundational agent in oncology combination regimens despite its age.
LOE Approaching
LOE-approaching status signals a mature, stable franchise with declining growth potential; commercial teams are likely focused on defending market share and managing generic transition rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome
Started Apr 2011
43 enrolled
Richter's Syndrome
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
Started Jul 2007
787 enrolled
B-cell Lymphoma
Career Relevance
Working on ONCOVIN offers stability in a legacy, defensible franchise with entrenched clinical use, but limited growth or innovation opportunities. Career trajectory favors operational excellence, cost management, and market access roles over commercial expansion or clinical development.
Worked on ONCOVIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.